Skip to main content
Premium Trial:

Request an Annual Quote

William Audeh

Agendia has appointed William Audeh as chief medical officer. Audeh will report to CEO Mark Straley and is responsible for translating complex laboratory science and personalized medicine diagnostics into actionable, patient-centered solutions for clinicians. Prior to joining Agendia, he served as the director of the Cedars-Sinai Cancer Center, medical director of the Wasserman Breast Cancer Risk Reduction Program, and associate clinical professor of medicine at the University of California, Los Angeles David Geffen School of Medicine. Audeh has also been the principal investigator on a wide variety of both national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.